TSHZ2

Across TCGA pan-cancer cohorts, TSHZ2 Mutation is linked to patient survival in 17 of 34 cancer types, making it a survival-associated TSHZ2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher TSHZ2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TSHZ2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BLCA show a favorable association.

THYM, STAD, and SCLC are the cancer types where TSHZ2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
STAD	OS	Median	II,III,IV	0.111	0.711	<.001	39	view →
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	24	view →
HNSC	DFS	Median	III,IV	0.125	0.685	<.001	23	view →
KIRP	DFS	Median	All	0.115	0.867	<.001	18	view →
SKCM	OS	Median	II,III,IV	0.848	0.708	.004	16	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
PAAD	DFS	Median	All	0.175	0.487	.008	12	view →
BLCA	OS	Median	II,III,IV	0.892	0.411	.039	12	view →
UCEC	DFS	Median	All	0.961	0.826	.012	8	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

TSHZ2–THYM (OS)

Open the THYM breakdown →